<75% participation

The Vendys II, an FDA-approved device, uses finger digital thermal monitoring (DTM) after a period of blood flow restriction to evaluate vascular health. This study will evaluate the feasibility of using this device to measure the Vascular Reactivity Index (VRI) in children and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT).

Primary Objective:

-Assess the feasibility of the use of VENDYS-II in children and AYA as a measure of vascular endothelial function, where feasibility is defined as completion of the evaluation by at least 70% of consented participants.

Secondary Objective:

-Summarize the incidence of any adverse events that precludes completion of assessment of endothelium-dependent vasodilation using the Vendys II in children and AYA.

Inclusion Criteria for HCT candidates:

• Children, adolescents and young adults (AYA) 6-26 years of age who are HCT candidates

• Recipients within 30 days prior to or within 14 days after autologous and allogeneic HCT.

  -. Any preparative regimen.

• Willing and eligible to enroll on PA19-0756

Inclusion Criteria for Healthy Donors:

- Healthy HCT donors between the ages of 6-26 years of age.

Exclusion Criteria:

• Any subject who does not consent/assent to participation.

  -. Any subject with an injury or deformation to the index finger which prevents proper fit of the device.

• Any subject with skin toxicity or neuropathy which prevents comfortable use of the device.